Brind.
  1. GlaxoSmithKline, Moderna, and Sinovac are leveraging the influenza vaccine market, with Phase 3 trials showing strong immune responses.

Moderna's vaccine demonstrated superior efficacy compared to GSK's flu shot on July 1, 2025.

2 reports, 0 independent Updated Jul 1
Gone quiet
Reports
2
Developments
2
Repetition
50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

SpeculativeNo independent reporting found

Moderna's vaccine demonstrated superior efficacy compared to GSK's flu shot on July 1, 2025.

Who's involved

What this event is mainly about
ModernaGSK

How it developed

Newest first. Tap a step to see who reported it.
  1. Positive test results were reported for Moderna's flu vaccine.Sub-event
  2. Moderna's vaccine showed superior efficacy to GSK's flu shot.

Keep exploring

Part of

GlaxoSmithKline, Moderna, and Sinovac are leveraging the influenza vaccine market, with Phase 3 trials showing strong immune responses. All 2 developments

The entities involved

Related events

Coverage

Newest first; wire copies grouped
  • Unknown outlet
  • Unknown outlet